CONMED Corp Amended Passive Investment Disclosure
The Vanguard Group filed an amendment (Schedule 13G/A) reporting zero beneficial ownership of CONMED Corp common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
The Vanguard Group filed an amendment (Schedule 13G/A) reporting zero beneficial ownership of CONMED Corp common stock. The filing states 03/13/2026 and is signed on 03/26/2026. It explains an internal realignment on January 12, 2026 that caused separate reporting by Vanguard subsidiaries and business divisions. The filing lists 0% ownership and 0 shares, and states no single external person holds more than 5% of the class.
Insights
Vanguard reports no beneficial stake in CONMED after internal realignment.
The filing explicitly lists 0 shares and 0% ownership as of 03/13/2026, signed 03/26/2026. It attributes separate reporting to an internal realignment on January 12, 2026 under SEC Release No. 34-39538.
Because the filing shows disaggregation of prior holdings among Vanguard affiliates, subsequent filings from the named subsidiaries may show redistributed positions; current cash‑flow treatment and any subsidiary schedules are not included in this excerpt.
AI-generated analysis. How Rhea-AI works. Not financial advice.